ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ACS Goal To Raise Percentage Of Women Who Get Mammograms

July 31, 1992

GAO Eppley Report Offers Lessons for Grantees, Contractors

March 3, 1978

Tighter Payment Policy

November 5, 2010

DCT Board Approves Lung Cancer Drug Discovery Project, First Targeted Anticancer Agent Search

June 22, 1984

NCI Predicts 42 Percent Increase In Number of Senior Survivors

October 28, 2011

NCI Releases List of Cancer Center Core Grant Funding for FY 2005; Univ. of New Mexico is the Newest NCI-Designated Center.

March 3, 2006